Global Biomedical R&D Compute Tidal Scheduling — 10 Deep Case Studies

Core Thesis: Biomedical R&D is the most extreme, complex, and unpredictable industry for global compute tides. Virtual screening for a single drug molecule can consume 10,000 GPUs within 72 hours, followed by nearly zero load for the next 3 months. KAI.com does not exist to make compute cheaper—it monetizes the industry’s “compute windows,” compressing drug development timelines from 10 years to 3 years. 一、生物医药研发的"算力潮汐周期" | I. The Compute Tidal Cycle in Biomedical R&D

The typical lifecycle of a drug is 10-15 years, with compute demand fluctuating violently across stages. Key insight shows that a pharma company utilizes less than 40% of its compute capacity 90% of the time because: (1) Pipelines do not require heavy compute during clinical stages; (2) Virtual screening cycles of different projects naturally stagger; (3) Molecular dynamics simulations are highly suitable for checkpoint-restart running. This is KAI.com’s core arbitrage space. 阶段 / Stage

Screening

Optimization

clinical

Clinical Trials

Submission

Compute Demand

Max)

Negligible)

Resource Type GPU狂暴 / GPU Rampage GPU中度 / GPU Medium GPU低度 / GPU Low

CPU Analytics CPU低度 / CPU Low

Duration 2 - 4 周 / Weeks 3 - 6 个月 / Months

Months 5 - 8 年 / Years

Months

Feature

Steady baseline computation

Screening

Optimization

clinical

Clinical Trials

Submission 80% load consumed in 4 weeks 95% of GPUs running in labs Compute sits idle until the next pipeline cycle

Spin-off) — UK/Switzerland

Core Compute Scenario Protein-ligand interaction prediction via AlphaFold 3 / IsoDDE engines. IsoDDE, released in 2026, was hailed by Nature as an “AlphaFold 4-level breakthrough.” Compute Tidal Curve Demand is strictly driven by the discovery cycle:

  1. Target Discovery (2-4 weeks): Predicts 10,000 target structures; requires 5,000 GPUs 24/7 (95% utilization).
  2. Virtual Screening (3-6 weeks): Docking & scoring of 5M molecules; burst demand for 10,000 GPUs (100% utilization).
  3. Lead Optimization (3-6 months): MD simulations
  • ADMET prediction; requires 2,000 GPUs (40% utilization).
  1. Clinical Waiting (6-18 months): Waiting for trial data; utilization drops below 5%. Tidal Waste Owns ~8,000 H100 GPUs with an annualized average utilization of 35%. Wastes ~45.55M GPU-hours/year. At $3/hour, this equals $137M/year in idle losses. KAI.com Scheduling Solution KAI.com dynamically orchestrates Isomorphic’s idle GPUs to Moderna (US overnight mRNA design), Takeda (London night shift running Japan’s MD simulations), and WuXi AppTec. Security Isolation: Utilizes Trusted Execution Environments (TEE + Federated Learning). Training data remains encrypted; weights are never leaked. Financial Return: Recovers $68 Million/year in idle compute value for Isomorphic Labs.

Salt Lake City, USA

GPU。

Core Compute Scenario Operates BioHive-2, the pharma industry’s largest supercomputer (built by NVIDIA, TOP500 top 50). Generates 2.2M cell images daily for AI-driven phenomics mapping. Compute Tidal Curve Alternates between wet-lab and dry-lab cycles on a weekly basis:

  1. High-Throughput Wet Lab (3 days/week): Image segmentation & feature extraction for 2.2M samples; requires 3,000 GPUs.
  2. Data Analysis (2 days/week): ML model training & correlation analysis; requires 5,000 GPUs.
  3. Model Inference (2 days/week): Virtual screening; requires only 500 GPUs.
  4. Partner Interventions (1-4 weeks): Intermissions between Roche/Bayer/Sanofi projects; utilization drops to 20%. Tidal Waste BioHive-2 holds 4,000 high-end GPUs (H100/A100). Baseline utilization hits a low of 20%, generating an annual idle cost of $60M - $80M. KAI.com Scheduling Solution KAI.com routes Recursion’s idle windows to European biotechs (Evotec, Boehringer Ingelheim) during their daytime, and to Asian molecular simulations overnight. Compute Credit Bank: Recursion deposits idle capacity to earn KAI Credits, which are redeemed for external GPU bursts during peak cycles. This “Time Bank” architecture cuts annual compute costs by 20%.

Core Compute Scenario mRNA sequence design (Transformer-based translation efficiency and stability prediction) and LNP (Lipid Nanoparticle) formulation optimization via MD simulations. Compute Tidal Curve Driven by the “Pandemic Cycle” — perhaps the most volatile tide on Earth:

  1. Outbreak Phase: Instantly demands 10,000+ GPUs for 48-hour sequence design, followed by 4-6 months of continuous 24/7 LNP simulations.
  2. Baseline Operations: Routine upgrades for seasonal flu/RSV vaccines require 2,000-3,000 GPUs (40-50% utilization).
  3. Inter-Project Gaps (2-3 times/year): Post-IND submission windows pull utilization below 10%. The Fatality of Compute Waste The “Dual-Peak Paradox”: Moderna must maintain a 10,000-GPU footprint for bio-security. Shorthandedness during a pandemic means a 2-week delay ($Billiions lost + lives). Yet, 60% sits idle normally, wasting $200M+/year. KAI.com Scheduling Solution Pandemic Compute Option: Moderna pays a $30M/ year option fee to guarantee 10,000 GPUs on-demand within 30 minutes of a WHO/health alert. Normally, KAI markets this reserved pool to Isomorphic or Recursion as pre-emptible, lower-priority capacity. Financial Impact: Slashes annual compute costs from $263M (self-held) to $90M (option + usage), a 65% savings.

500-800 GPU。

Core Compute Scenario Individualized Neoantigen Specific Immunotherapy (iNeST). Pipeline: Tumor sequencing → AI neoantigen prediction → Tailored mRNA design → Formulation optimization per patient. Compute Tidal Curve Personalized medicine implies “zero batch effect” — hyper-isolated, sudden computing tasks:

  1. Patient Influx Peaks (Quarterly): New clinical trial openings register 50-200 patients concurrently. Each requires 500 GPU-hours, generating a massive 25k-100k GPU-hour surge in 3 weeks.
  2. Routine Operations: 3-5 patients/day; requires 500-800 GPUs.
  3. Clinical Waiting Window: Post-trial data tracking drops GPU utilization below 20%. KAI.com Scheduling Solution Personalized Medical Grid & GDPR Compliance: BioNTech’s internal cluster (~2,000 cards, 35% utilization) joins the pool. German night-shifts are sold to US/Asian day-shifts. During peak registration, KAI reclaims the cluster within 15 mins and provisions backup from Paris/London node links. To satisfy strict GDPR constraints regarding genetic data, KAI enforces a “Domestic Tide” architecture where patient data never leaves Germany, moving the containerized models instead of raw data.

Global

60-70%（5,000-7,000 GPU）。

Core Compute Scenario The world’s leading CRDMO serving 500+ global clients. It runs a highly heterogeneous multi-tenant compute infrastructure fluctuating wildly across varying client scales. Compute Tidal Curve Aggregated client tasks should theoretically smooth out, but Chinese biopharma schedules are highly synchronized with “Dual-Submission” deadlines (FDA/ NMPA timelines):

  1. Dual-Submission Sprint (March & September): Concentrated IND/NDA filings push pharmacology/ toxicology compute to 10,000+ GPUs at full capacity for 4-6 weeks.
  2. Routine Operations: Baseline runs at 60-70% capacity (5,000-7,000 GPUs).
  3. Golden Week / Chinese New Year: Projects halt; utilization falls to 20-30%. Tidal Waste WuXi manages ~15,000 GPUs. Compute idling during Chinese New Year costs around ¥80M/week, generating an aggregate holiday waste of ¥400M - ¥500M ($60M+) annually. KAI.com Scheduling Solution Cross-CRDMO Elastic Pool: During domestic holidays, KAI exports WuXi’s massive idle capacity to Western or Indian biotechs. Conversely, during Thanksgiving, Christmas, or Diwali, WuXi imports low- cost, off-peak capacity from overseas. This cross- border mesh generates ¥300M - ¥400M/year in structural value, turning WuXi into an active compute market maker.

Basel, Switzerland / South San Francisco, USA

Core Compute Scenario Large-scale whole-genome sequencing (WGS) data analytics (1,500 samples/day, 375 TB data generated) and clinical trial AI design optimization spanning 80+ countries. Compute Tidal Curve Total Demand = Genomics (steady baseline) + Clinical Trials (cyclical spikes). The two waves are naturally complementary, making them highly predictable:

  1. Genomics Analysis: Continuous baseline requirement of 800-1,200 GPUs.
  2. Clinical AI Spikes: Quarterly interim analysis reports trigger a sudden need for 5,000 GPUs for 2-3 weeks.
  3. Regulatory Filing: Pre-submission statistical modeling for FDA/EMA occurs 1-2 times/year, requiring 3,000 GPUs for 1-2 weeks. KAI.com Scheduling Solution Clinical Trial Compute Futures: Capitalizing on Roche’s predictable cycles, KAI structures “Compute Futures Contracts” for upcoming regulatory filing windows. Roche locks in capacity ahead of time at a 40-50% discount. Local-First Reverse Routing: During off-peak windows, Roche’s Basel nodes are routed by KAI to neighbor Novartis (whose cycles are inverted) and the Swiss BioCluster Zug, keeping network latencies below <1ms.

Denmark

Core Compute Scenario Ultra-long-scale molecular dynamics (MD) simulations (microsecond to millisecond scale) for designing and optimizing hyper-growth GLP-1 receptor agonists (Semaglutide). Compute Tidal Curve Driven entirely by “Nordic Power Grid Tides” rather than business pipeline gaps. Data centers utilize 100% wind/hydro power:

  1. Summer/Autumn (Power Surplus): Massive hydro/wind oversupply slashes grid pricing. Novo concentrates heavy MD simulations and screening here, using 5,000 GPUs.
  2. Winter (Heating Peak): Grid costs skyrocket due to heating demands. Novo curtails cluster operations to 1,000-2,000 GPUs, leaving 3,000-4,000 GPUs completely unutilized but available for export. KAI.com Scheduling Solution Green Compute Premium (ESG Pricing): KAI flags Novo’s off-peak capacity as “100% Renewable Certified.” This capacity commands a 15-20% ESG green premium from pharma giants with strict Net- Zero carbon mandates (AstraZeneca, Pfizer). Cross-Hemispheric Matching: KAI matches Denmark’s winter surplus with the Southern Hemisphere’s operating peaks (e.g., Australia’s CSL during their summer). This architecture generates an annualized gain of $35M - $48M for Novo Nordisk.

Core Compute Scenario AI-driven drug repurposing for rare diseases across 80+ pipeline products. GPU loads center on knowledge graph reasoning, molecular docking, and real-world evidence parsing. Compute Tidal Curve The structural clash between traditional Japanese corporate culture and global R&D timelines:

  1. FY Start (April-May): Budget unlocks; projects launch; 2,000 GPUs instantly peak.
  2. National Holidays (August Obon & January New Year): The entire society synchronized-halts; cluster utilization collapses to 5-10%.
  3. FY End Sprint (March): Hard deadlines to close out projects trigger a severe deficit, requiring 3,000+ GPUs. KAI.com Scheduling Solution Nationwide Compute Export: During the Obon holiday, KAI offshores 15,000+ idling Japanese GPUs (Takeda, Astellas, Daiichi Sankyo) directly into Western R&D hubs. Utilizing time-zone arbitrage (Japan night = US day), “Japanese cards synthesize global medicine while employees rest.” Conversely, in March, KAI injects 2,000 auxiliary GPUs from off-peak Western centers into Tokyo nodes via InfiniBand paths with <100ms latency. This saves Takeda ¥2.0B - ¥2.5B JPY ($13M - $17M) annually.

500-1,000 GPU。

Core Compute Scenario Biosimilar structural bio-equivalence profiling and AI- driven bioreactor manufacturing automation involving real-time processing and continuous parameter optimization. Compute Tidal Curve A textbook “Global Pharma Foundry Tide.” As India’s leading biopharma hub, its compute cycles mirror the regulatory timelines of Western clients:

  1. Western Filing Windows: Collaborative molecular matching for client IND/NDA submissions spikes demand to 2,000-3,000 GPUs.
  2. Intermittent Innovation: In-house biosimilar mapping consumes a steady 500-1,000 GPUs.
  3. Power Pricing Edge: Indian data centers enjoy structural power costs (~$0.08/kWh vs $0.12/kWh in the US), offering a native arbitrage foundation. KAI.com Scheduling Solution Pharma Foundry Arbitrage & “Compute-for- Cooperation”: KAI routes Biocon’s 40% idle capacity to European hubs leveraging India’s low-cost power footprint. Biocon deposits its surplus capacity into KAI to earn “Ecosystem Credits.” Beyond redeeming credits for peak capacity from nearby Singapore nodes (<30ms latency), Biocon stakes these credits to secure co- development rights and compliant data-sharing treaties with elite Western biotech firms, introducing a brand-new model of compute assetization.

Toulouse, France

Core Compute Scenario Operates a multi-client drug discovery framework serving 10+ legacy pharmaceutical giants (BMS, Sanofi, Novartis). Each tenant runs in isolated, high- security compute sandboxes. Compute Tidal Curve As Europe’s preeminent CRO, multiple client pipelines should theoretically smooth out compute loads, but synchronized sprints paired with strict European labor holidays create massive spikes:

  1. Overlapping Client Sprints (1-2 times/quarter): Simultaneous virtual screenings require 5,000-8,000 GPUs, blinding their 3,000-node internal cluster.
  2. Holiday Budget Freezes (August Summer & December Christmas): Client systems freeze; local GPU utilization falls off a cliff to 15-25%. KAI.com Scheduling Solution Multi-Lateral Market Making Paradigm: During Christmas/Summer breaks, KAI automatically shifts Evotec’s 2,800 idle cards to China’s WuXi AppTec (which operates normally through Western holidays) or South Korea’s Celltrion. When client sprints collide, KAI borrows 5,000 nodes from winter-curtailed Nordic networks or off-peak Genentech nodes. Evotec avoids capital spending for an 8,000-GPU cluster ($120M/ year), optimizing with a 3,000-GPU baseline + KAI elasticity to cut total compute costs by 42% ($50M saved annually).

Based on the 10 global pharmaceutical case studies, KAI.com evolves beyond a simple infrastructure layer. It forms a five-layer strategic moat customized for the high-security, volatile domain of life sciences: 价值层级 / Value Layer

(Security & Compliance)

GDPR + HIPAA + Sovereignty Architecture. Pharma assets are top-tier secrets. KAI enforces three containment tiers: • Tier 0: Raw genetic sequences never exit sovereign borders; • Tier 1 (TEE): Virtual screening executes inside encrypted hardware enclaves; hosts cannot spy on parameters; • Tier 2: Multi-tenant model training via Federated Learning; swaps gradients only.

(Cross-Pharma Liquidity)

Unlocking Peer-to-Peer Liquidity. Routes Roche’s idle overnight cards to Novartis, and balances WuXi’s holiday surplus against Recursion’s peaks. This is a game of trust and neutrality. KAI’s neutral multinational compliance framework provides the singular foundation for pharma to share compute.

(Financial Derivatives)

Compute Banking & Financial Options. First to introduce real commodity financial engineering to high- performance computing: • Time Bank (Recursion): Save idle capacity, withdraw during bursts; • Pandemic Options (Moderna): Guaranteed 30-min global preemption rights during alerts; • Futures (Roche): Forward-locks deep capacity discounts for clinical filing windows.

Sovereign Bio-Defense Infrastructure. When the next global pandemic triggers a

(Global Pandemic Response)

WHO alert, KAI can trigger emergency protocols within 30 minutes, dynamically preempting non-core capacity across all nodes into an aggregated 500,000+ GPU swarm, compressing vaccine design from 11 months to 3 months.

(Quantified Acceleration)

Empirical Timeline Compression (See Matrix Below). Eradicates the idle latency of computing gaps. Accelerates virtual screening by 4x, neoantigen mapping by 9x, and global drug R&D cycles from 10-15 years down to 5-8 years, yielding a net 2x development speedup. 附：KAI.com 核心场景加速量化测算 | Annex: Quantified Acceleration Across Core Scenarios

Without KAI 有 KAI 周期 / With KAI 净加速比 / Acceleration Ratio

(10M Library) 4 周 / Weeks 1 周 / Week 4.0x

Dynamics (1μs MD Simulation) 8 周 / Weeks 3 周 / Weeks 2.7x

Analytics (Interim) 3 周 / Weeks 1 周 / Week 3.0x

Prediction (iNeST)

Patient)

(Hours/Patient) 9.0x

Sequence Design 11 个月 / Months 3 个月 / Months 3.7x

R&D Industry Lifecycle 10 - 15 年 / Years 5 - 8 年 / Years

by half)

Dimension OpenRouter 核心表现

Core Value in Biopharma

Pandemic Outbreak Option

Holiday Compute Export

(GDPR) Data Sovereignty Isolation

Financial Derivatives

Moat & Defensibility

Biomedical R&D is defined by the most severe compute tides on Earth — where virtual screening for a single drug molecule can engulf 10,000 GPUs in 72 hours, only to face near-zero utilize rates for the subsequent quarter. Without KAI.com, every pharma entity globally is forced to over-provision and self-hold massive private GPU nodes to survive their volatile pipeline peaks, leading to structural idling and wasted capital 80% of

the year. With KAI.com, global pharma merges into a unified, high-liquidity “Compute Tidal Shared Pool.” While one company’s cluster sleeps during localized nights or public holidays, it securely fires up via encrypted meshes to fuel life-saving drugs for another across the globe. The ultimate manifestation of KAI.com in life sciences is: To guarantee that every single GPU on this planet continuously works for human health — regardless of corporate banner, sovereign boundary, or time zone. National lines, corporate silos, and commercial trade secrets cease to be friction points to global compute fluidics.